C ommercial spacefl ight participants (SFPs) will introduce new medical challenges to the aerospace community, with unique medical conditions never before exposed to the spacefl ight environment. Concern regarding the eff ect of acceleration forces on the cardiovascular system in subjects who are not anatomically or physiologically within the normal range, particularly SFPs with prior history of cardiac dysfunction or disease, has been expressed by aerospace medical professionals since the advent of the commercial spacefl ight industry. Among the multitude of concerns was the potential for elevated preload and aft erload, which could strain an already weak or abnormal heart or exacerbate valvular insufficiency with decreased cardiac output (CO) and cerebral perfusion. Such events could elevate the risk for G-induced loss of consciousness or induce earlier symptoms of decreased cerebral blood fl ow when compared to individuals without cardiac abnormality. As cardiac malformations, abnormalities, or the presence of signifi cant disease has long been held as indisputable criteria for disqualifi cation of individuals for fl ight-related (particularly high-acceleration) activities, data regarding the eff ects of acceleration upon known cardiac disease are limited.
C A S E R E P O R T C ommercial spacefl ight participants (SFPs) will introduce new medical challenges to the aerospace community, with unique medical conditions never before exposed to the spacefl ight environment. Concern regarding the eff ect of acceleration forces on the cardiovascular system in subjects who are not anatomically or physiologically within the normal range, particularly SFPs with prior history of cardiac dysfunction or disease, has been expressed by aerospace medical professionals since the advent of the commercial spacefl ight industry. Among the multitude of concerns was the potential for elevated preload and aft erload, which could strain an already weak or abnormal heart or exacerbate valvular insufficiency with decreased cardiac output (CO) and cerebral perfusion. Such events could elevate the risk for G-induced loss of consciousness or induce earlier symptoms of decreased cerebral blood fl ow when compared to individuals without cardiac abnormality. As cardiac malformations, abnormalities, or the presence of signifi cant disease has long been held as indisputable criteria for disqualifi cation of individuals for fl ight-related (particularly high-acceleration) activities, data regarding the eff ects of acceleration upon known cardiac disease are limited.
Preliminary studies have demonstrated that individuals with a wide range of prior medical history have been able to tolerate exposure to the acceleration environments anticipated for short-duration, suborbital spacefl ights. 2 , 3 Such studies postulated that the short duration of suborbital acceleration profi les limit the possibility of signifi cant medical events or adverse eff ects of acceleration exposure. Eff orts have been dedicated to demonstrating the tolerance of individuals with well-controlled medical disease to the G forces anticipated during suborbital fl ight, generally limited to less than or equal to +4 G z and +6 G x . Even so, concern remains regarding individuals with a multitude of medical concerns, particularly cardiovascular diseases, as though the amalgamation of numerous medical conditions might raise the risk of participation higher than singular, distinct, controlled conditions.
Th is is a case report regarding the response of a subject with multiple cardiac malformations, including aortic insuffi ciency (AI), pulmonary atresia, pulmonary valve replacement, ventricular septal defect (VSD) post-repair, right ventricular hypertrophy (RVH), and pulmonary artery stenosis (postcatheterization and dilation), to centrifuge acceleration simulating suborbital fl ight. Th is individual was exposed to centrifuge-simulated G-forces similar to those anticipated during the launch and reentry profi les of a short-duration, suborbital, commercial spacefl ight to evaluate his tolerance to such acceleration. His participation was part of a larger trial that has been previously published.
2

CASE REPORT
A 23-yr-old Caucasian man with a history of Tetralogy of Fallot volunteered for participation in the ongoing trial. 2 His past medical history was signifi cant for multiple congenital cardiac malformations in association with the Tetralogy syndrome, including a membranous VSD, overriding aorta, pulmonary atresia, and RVH. He had undergone staged repair as an infant, including two unifocalizations of major aorto-pulmonary collaterals, followed by complete intracardiac repair at age 4, with placement of a pulmonary artery homograft with an outfl ow patch and VSD closure. He had a further history of multiple vascular stenoses in both lungs and had undergone catheterization and pulmonary artery balloon angioplasty at age 15 for his right middle-and lower-lobe pulmonary arteries. At the time of his catheterization, it was determined that he had nearly free pulmonary valve regurgitation, though right ventricular (RV) size was only mildly increased. At that time, he had a bovine pulmonary valve replacement without complication. He had undergone continuous electrocardiographic monitoring at age 15, with electrocardiograms (EKGs) demonstrating primarily normal sinus rhythm with right bundle branch block, with heart rate (HR) ranging from 74-145 bpm, with an average of 91 bpm, mild asymptomatic ectopy, and occasional premature atrial complexes and premature ventricular complexes (PVCs). An echocardiogram performed at age 16 demonstrated dilation of the RV with ejection fraction of 52%, with mild-to-moderate RVH, trivial tricuspid regurgitation, trace mitral regurgitation, and mild AI with a dilated aortic root.
At the time that he volunteered for the study, he had been monitored and deemed in stable condition for over 6 yr, with cardiologists continuing to monitor his mild/moderate RV dilation and mild AI. According to his personal physician and cardiologist, he had been moderately physically active for many years, regularly engaging in aerobic activity, including cycling and physical education activities without limitations. He could tolerate non-incline ambulation indefi nitely and could manage multiple fl ights of stairs without increased work of breathing. Th e patient stated he occasionally noted himself winded aft er riding his bicycle up moderate inclines, but otherwise reported no abnormal symptoms to mild or moderate physical activity. EKG demonstrated only right bundle branch block with occasional PVCs, and no electrical evidence of RVH. He denied use of any medication.
Physical exam demonstrated a well-developed and wellnourished man, height 66 " and weight 165 lb. His baseline HR was 71 bpm, baseline blood pressure (BP) 125/70 mmHg, and baseline oxygen saturation 98 -100%. He had mild baseline jugular venous distension, but had no increase in distension with hepatojugular refl ex. Cardiac auscultation demonstrated a 3/6 long blowing murmur loudest at the base and a low-pitched early diastolic murmur following the second heart sound. Extremities were warm and pink, and bilateral upper-and lower-extremity pulses were symmetric. He was observed to be capable of managing multiple fl ights of stairs without diffi culty during his exam.
Based upon his stable cardiac condition and reasonable cardiovascular fi tness, and with no objections from either his personal physician or cardiologist, the subject was approved for participation in the study. After informed consent, he underwent 7 centrifuge runs over 2 d as part of a larger trial of 86 individuals conducted at the National AeroSpace Training and Research (NASTAR) Center centrifuge and approved by the University of Texas Medical Branch Institutional Review Board.
2 Day 1 consisted of two +G z runs (peak 5 +3.5 G z , run 2) and two +G x runs (peak 5 +6.0 G x , run 4). Day 2 consisted of three runs approximating suborbital spacefl ight profi les (combined +G x /+G z ). Data collected included BP, EKGs, pulse oximetry, neurovestibular exams, and post-run questionnaires regarding motion sickness and other symptoms.
At the testing facility, resting BP and HR were recorded prior to initiating the centrifuge runs. Th e participants were taught basic anti-G straining (AGSM) and the " hook " (L-1 closedglottis variant) maneuver and were advised to strain as needed by pressing on adjustable rigid pedals located on the gondola fl oor, but to use the hook maneuver only for greyout symptoms. Audiovisual simulation consisted of a projected monitor screen with cockpit-simulated images imitating real-time window views throughout the spacefl ight profi le, with matching fl ightrelated sounds, such as rocket engine fi ring, designed to create an experience for the participants as close to an actual suborbital fl ight as possible. 2 Despite the subject ' s signifi cant medical history, he had no abnormal physiological responses to the centrifuge trials. Th e subject generally demonstrated a slightly higher than average HR response during peak accelerations of all profi les when compared to subjects in the cardiovascular cohort of the larger trial, though this fi nding was not statistically signifi cant. 2 His post-spin HR ). Th ere were no other abnormal rhythms observed in this subject. Oxygen saturation was maintained at 98 -100% by pulse oximetry before, aft er, and during all centrifuge trials.
Th e subject reported no subjective symptoms of palpitations or discomfort during any of the runs and his neurovestibular exams demonstrated only mild imbalance aft er later runs, not significantly different from expected imbalance following repetitive centrifuge exposure. 2 He also reported mildly increased work of breathing during high +G x exposures, which was reported by 72% of the subjects of the larger study. 2 He did note mild greyout during +G z onset of run 4 (+G z only run, with max +3.5 G z ) and stated that he had forgotten to perform AGSM at the start of the acceleration profi le. He further stated that all symptoms of greyout resolved with initiation of only gluteal muscle contraction, and that he had no need of the full AGSM and hook maneuver.
Th e subject ' s pre-spin and post-spin systolic and diastolic BP were not signifi cantly diff erent from the average BP of the subjects in the larger trial cardiac cohort. 2 His average HR immediately prior to centrifuge runs was 114 bpm, which is not signifi cantly diff erent from the averages of either the control group, matched for age, or the cohort average ( Table I ) . His average HR immediately following centrifuge runs ( Յ 1 min of cessation) was 125 bpm, which was found to be significantly higher than the control group ' s average of 85 6 10 bpm (t 7 5 2.36, P , 0.01). However, subject HR values during the dynamic phases of peak accelerations during any trial were found to be of no signifi cant diff erence to those of control subjects matched for age and sex (see Table II ). When asked how he was feeling during times of tachycardia, he denied pain or discomfort, demonstrated no clinical symptoms of tachycardia or hemodynamic compromise, and stated only that he was very excited about the experience.
DISCUSSION
Potential risks to SFPs with AI or valvular dysfunction include lower +G z tolerance, earlier symptom onset from decreased cerebral perfusion, and ineff ective mitigation strategies such as AGSM due to the inability of an insuffi cient aortic valve to withstand prolonged Valsalva. Th ere are no known prior studies of prolonged accelerations approximating spacefl ight in such individuals. Th is case demonstrates tolerance of acceleration profi les in an otherwise young and healthy individual with signifi cant cardiac malformations, including valvular insufficiency and artifi cial (xenographic) valve replacement, and a prior history of pulmonary artery angioplasty.
Signifi cant concerns were raised during consideration of this subject for inclusion in the trials. First, there was concern regarding the inclusion of a subject with known arterial stenosis, status-post revascularization procedures. Th e most significant concern following pulmonary artery angioplasty or other percutaneous interventions is the potential for restenosis, most commonly seen within 3-6 mo following intervention. 4 As this subject had been stable for years without evidence of restenosis, he was considered to be at very low risk for an adverse event secondary to unrecognized restenosis of pulmonary vasculature. Further, this subject was undertaking the role of passive participant, as would a commercial SFP. Th us, the potential for sudden incapacitation from hemodynamic compromise does not carry the same risks for an SFP as it would for a pilot of an aircraft . 2 Finally, previous studies have demonstrated unimpeded performance of individuals with revascularized coronary artery disease under similar acceleration exposure. It was felt that the risk for revascularized pulmonary vessels would not likely be greater than that of coronary vessels. 2 , 3 Th e subject has a known history of AI, mild by echocardiogram. Even so, concerns were raised regarding whether or not aortic regurgitation secondary to acceleration forces or to AGSM-related alterations of preload/aft erload might lead to decreased tolerance to acceleration forces, with increased risk of G-induced loss of consciousness or other symptoms of decreased cerebral perfusion. Th ere was also concern expressed regarding whether or not exposure to acceleration may cause an adverse progression of his disease, with worsening aortic morphology and increased regurgitation. Valvular insuffi ciency and its impact on acceleration tolerance, as well as the impact of acceleration exposure on valvular morphology, have been well studied. One study demonstrated that prolonged and repetitive exposure to high G forces, specifi cally . +9 G z , over many years is associated with pulmonic insuffi ciency and tricuspid regurgitation, though no such association was demonstrated for aortic or mitral valves. 8 Another, larger study failed to detect any cardiac structural or functional abnormality (including right and left ventricular dimensions, wall thickness, aortic and atrial dimensions, and valvular infl ow velocities) in active pilots regularly fl ying high-performance (+7 G z for . 15 s) sorties when compared to pilots fl ying low-performance (low G) aircraft . 5 Other data have demonstrated that aviators exposed to sustained high G fl ying (+5 G z for 60 s or longer for . 4 yr) show no evidence on repeated echocardiography of alterations to valvular morphology or integrity. 1 , 6 As this study sought to expose subjects to comparatively low +G z for relatively short periods of time ( Յ 15 s), the risk of worsening the subject ' s condition by induced morphological changes was thought to be negligible.
Literature was not found to specifi cally address the potential for decreased CO (and, therefore, decreased +G z -tolerance from poor cerebral perfusion) in individuals with aortic regurgitation, likely because such individuals are generally excluded from such studies. However, aircrew with mild AI are considered by the FAA to be fi t for unrestricted fl ying activity without concern for increased susceptibility to adverse acceleration eff ects. 4 It was, therefore, felt that the moderate +G z exposure in this study would likely be well tolerated by the subject despite his mild AI.
Th e presence of a xenographic bioprosthetic valve was a further cause of concern. Th e FAA has granted Special Issuance of Class I medical certifi cates to pilots with aortic valve replacement, limiting such pilots to no more than +3 G z acceleration loading; 7 however, cases involving pulmonary valve replacement are more diffi cult to identify. One concern for aortic bioprostheses is insuffi ciency under high +G z exposure, thought to be eff ectively mitigated by limitation to Յ +3 G z . 7 Th is risk would be lower for pulmonary valve replacement as transient G-induced pressure gradients are lower across the pulmonary valve than the aortic valve. Another concern regarding xenographic valve replacement was the risk for thromboembolism. Th is risk is highest within 6 mo of surgery and was, therefore, deemed to be low risk in this subject, 8 yr postsurgical replacement and without thromboembolic complications. 10 Th ere are few studies regarding cardiovascular function, particularly CO response, of even normal hearts under high +G x exposure, a cause for further concern in an individual with known cardiac morphology abnormalities. Prior studies have demonstrated no signifi cant alteration to CO following sustained exposure for up to 10 min at +5 G x in normal airmen.
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As a result, we felt it unlikely that a subject with only mild AI and mild/moderate RV dilation would be signifi cantly aff ected by +G x exposure. Indeed, the subject denied symptoms during any +G x centrifuge trials, demonstrating comparatively normal tolerance to the moderate +G x exposures.
Finally, signifi cant concern was raised regarding the acceptance of a subject with a multitude of cardiac malformations. Despite relative comfort with one or two of this subject ' s conditions, the combination of all conditions raised concerns regarding cumulative risk. We were unable to identify prior studies of an individual with multiple cardiac malformations and abnormalities exposed to +G z and +G x accelerations as in this study and, as mentioned above, pilots who have been granted aeromedical certifi cation following valve replacement are generally confi ned to low-acceleration fl ight profi les of Յ +3 G z , without the mixed +G z /+G x experienced herein. However, it was felt that, given the information presented above, each of the subject ' s medical conditions was well controlled, and that he was at relatively low risk for adverse outcome during his participation. Th e graduated acceleration profi les used in this study allowed medical observers to monitor his performance and intervene, if necessary, prior to higher acceleration exposures. As each of his conditions represented an apparent low risk of adverse outcome, the subject was deemed likely to tolerate the moderate accelerations of a simulated commercial suborbital spacefl ight.
Th is case represents a single individual ' s tolerance to moderate +G z /+G x acceleration exposures, representative of those potentially experienced during a commercial, suborbital spacefl ight. Th is individual ' s experience cannot be considered representative of all persons with similar disease or abnormal morphologies. In fact, the ability to draw conclusions from this one individual ' s performance is severely limited. First, the subject was anthropometrically predisposed to the likelihood of tolerance to +G z exposures seen here, as he is relatively shortstatured (66 " ), with a resultant short hydrostatic column requiring less pressure to achieve adequate cerebral perfusion. His known AI was mild and stable, followed for a number of years with stable imaging, and is not representative of all individuals with known AI or valvular defect. His pulmonary valve replacement was similarly remote and stable to follow-up. Furthermore, pulmonary valves are not exposed to the increased pressure gradients seen across aortic valves during AGSM and, therefore, his tolerance cannot be considered representative of all valve replacements and relative performance. Similarly, his pulmonary stenosis had been well managed with pulmonary artery angioplasty, without evidence of restenosis. However, pulmonary stenosis should not be considered representative of, for example, coronary stenosis or similar disease. Additionally, this study was not designed to evaluate his cardiovascular morphological responses or compensation to acceleration exposure. No invasive monitoring was performed, and no imaging before, during, or aft er acceleration exposure was required for his participation. As a result, we are unable to present cardiac chamber or valvular pressures or CO during centrifugation. Finally, this study could not evaluate cardiovascular response to microgravity. Microgravity exposure causes a substantial fl uid shift and alterations of CO, which could be problematic for individuals with compromised diastolic function and should be evaluated with more detailed studies. 9 Th e intent of the study was not to provide generalizations regarding the ability of individuals such as this to tolerate centrifuge acceleration. We sought only to demonstrate that individuals with concerning medical histories can be evaluated without automatic disqualifi cation and may be deemed lower risk than initial evaluation might lead aerospace medical specialists to believe. Th is individual is young and, despite his medical history, relatively healthy with reasonable cardiovascular fi tness. He was able to tolerate (and, in fact, enjoy) the centrifuge experience, as presented here, without evidence of any abnormal hemodynamic or physiological responses. Similar cases may present themselves as potential candidates for suborbital spacefl ight. Evaluation and consideration of such individuals could help expand the realm of known medical conditions capable of tolerating acceleration exposure for the benefi t of scientifi c knowledge and provide previously impossible opportunities for individuals with such disease. Further, demonstration of tolerance in this young and otherwise relatively healthy individual may off er a precedent for the evaluation of older individuals with other signifi cant medical conditions. We believe that this work lays the foundation for further studies designed to evaluate individuals with reasonable cardiovascular compensation, despite concerning conditions, for the potential to tolerate suborbital spacefl ight acceleration profi les. Such work may someday permit inclusion in the commercial arena of those previously believed to be too high-risk, perhaps allowing even those with signifi cant medical conditions to pursue their own dreams of spacefl ight.
